Next 10 |
home / stock / icpt / icpt articles
Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share i...
New analysis demonstrates the impact of OCA on achievement of GGT <3.2×ULN and ALP <1.5×ULN Findings suggest that OCA has the potential t...
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. ("Alfasigma") and Intercept Pharmaceuticals, Inc. ("Inte...
NEW YORK, Oct. 21, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
NEW YORK, Oct. 08, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences, Inc. (NASDAQ:RENB) Lifshitz Law PLLC announces an investigation into possib...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intercept Pharm...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...